A biotech company developing bispecific antibodies for immunological and inflammatory (I&I) disorders. Bambusa Therapeutics was founded in May 2024 and has two lead programs: BBT001 and BBT002, which ...

The US Food and Drug Administration (FDA) late Friday approved a label expansion for Netherlands-based argenx’ (Euronext & Nasdaq: ARGX) Vyvgart efgartigimod alfa-fcab) and Vyvgart Hytrulo ...

Privately-held French drugmaker Pierre Fabre Pharmaceuticals says it has reached agreement with the US Food and Drug ...

North Carolina, USA-based clinical-stage gene therapy company Atsena Therapeutics has presented data from three studies at ...

Avalo Therapeutics’ shares surged 34%, after the US clinical-stage biotech announced positive top-line results from its Phase ...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended approval for US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Rybrevant (amivantamab). All the news that moves the ...

A clinical-stage immunology company based in the United States, operating within the Boston biotechnology ecosystem. Poplar Therapeutics was previously known as Phylaxis Bioscience and was ...

The US Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare beneficiaries access to certain GLP-1 ...

US oncology company Citius Oncology (Nasdaq: CTOR) has secured up to $36.5 million in new financing as it attempts to ...

The progressive pulmonary fibrosis market across the seven major markets is forecast to grow from $1.3 billion in 2025 to ...

British drugmaker GSK (LSE: GSK) is paying up to $1 billion to partner with China’s Siran Biotechnology on an experimental gene-silencing therapy designed to reduce visceral fat, reflecting a growing ...

Swiss contract development and manufacturing organization (CDMO) Lonza (SWX: LONN) and US pharma major Bristol Myers Squibb (NYSE: BMY) today announced an exclusive single-target licensing agreement.